Outset Medical (OM) director receives 18,667 RSUs grant on board role

Rhea-AI Filing Summary

Outset Medical director Karen Prange reported an equity grant from the company. On January 9, 2026, she was awarded 18,667 shares of common stock in the form of Restricted Stock Units (RSUs) at a reported price of $0.0 per share, meaning she did not pay cash for the grant.

Each RSU represents the right to receive one share of Outset Medical common stock. The RSUs are scheduled to vest quarterly over three years, and Prange must continue her service with the company through each vesting date to receive the underlying shares. After this grant, she beneficially owns 18,667 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prange Karen

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		18,667(1)	A	$0.0	18,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") granted to the reporting person on January 9, 2026. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest quarterly over three years, subject to the reporting person's continued service through the applicable vesting date.

	By: John L Brottem For: Karen Prange	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Outset Medical (OM) disclose in this Form 4 filing?

The filing reports that director Karen Prange received an award of 18,667 Restricted Stock Units (RSUs) of Outset Medical common stock on January 9, 2026.

How many shares did Karen Prange acquire according to the Form 4?

Karen Prange acquired 18,667 shares of Outset Medical common stock in the form of RSUs, and her beneficial ownership after the transaction is 18,667 shares, held directly.

What are the key terms of Karen Prange’s RSU grant at Outset Medical (OM)?

The grant consists of Restricted Stock Units, each representing one share of common stock. The RSUs vest quarterly over three years, conditioned on her continued service through each applicable vesting date.

Did Karen Prange pay cash for the 18,667 Outset Medical shares?

No. The transaction is reported with a price of $0.0 per share, indicating it is an equity grant rather than an open-market purchase.

What is Karen Prange’s relationship to Outset Medical?

She is reported as a director of Outset Medical and is not listed as an officer or 10% owner in this filing.

How will the RSUs reported in this Form 4 convert into Outset Medical shares?

Each RSU represents a contingent right to receive one share of Outset Medical common stock, which will be delivered as the units vest quarterly over three years, subject to her continued service.